Tags

Type your tag names separated by a space and hit enter

Management of diastolic heart failure.

Abstract

Diastolic heart failure (HF) is also referred to as HF with preserved left ventricular systolic function. The distinction between systolic and diastolic HFs is a pathophysiological one and isolated forms of left ventricular dysfunction are rarely observed. In diastolic HF left ventricular systolic function is normal or only slightly impaired, and the typical manifestations of HF result from increased filling pressure caused by impaired relaxation and compliance of the left ventricle. The predisposing factors for diastolic dysfunction include elderly age, female sex, obesity, coronary artery disease, hypertension and diabetes mellitus. Treatment of diastolic HF is aimed to stop the progression of the disease, relieve its symptoms, eliminate exacerbations and reduce the mortality. The management should include antihypertensive treatment, maintenance of the sinus rhythm, prevention of tachycardia, venous pressure reduction, prevention of myocardial ischemia and prevention of diabetes mellitus. The European Society of Cardiology specifies the type of therapy in diastolic HF based on: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, non-dihydropyridine calcium channel blockers, diuretics. In order to improve the currently poor prognosis in this group of patients the treatment of diastolic HF must be optimised.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    3rd Department and Clinical Ward of Cardiology, Poland. ania.kazik@wp.pl

    ,

    Source

    Cardiology journal 17:6 2010 pg 558-65

    MeSH

    Cardiovascular Agents
    Diastole
    Drug Therapy, Combination
    Heart Failure, Diastolic
    Humans
    Practice Guidelines as Topic
    Stroke Volume
    Systole
    Treatment Outcome
    Ventricular Dysfunction, Left
    Ventricular Function, Left

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    21154257

    Citation

    Kazik, Anna, et al. "Management of Diastolic Heart Failure." Cardiology Journal, vol. 17, no. 6, 2010, pp. 558-65.
    Kazik A, Wilczek K, Poloński L. Management of diastolic heart failure. Cardiol J. 2010;17(6):558-65.
    Kazik, A., Wilczek, K., & Poloński, L. (2010). Management of diastolic heart failure. Cardiology Journal, 17(6), pp. 558-65.
    Kazik A, Wilczek K, Poloński L. Management of Diastolic Heart Failure. Cardiol J. 2010;17(6):558-65. PubMed PMID: 21154257.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Management of diastolic heart failure. AU - Kazik,Anna, AU - Wilczek,Krzysztof, AU - Poloński,Lech, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/3/26/medline SP - 558 EP - 65 JF - Cardiology journal JO - Cardiol J VL - 17 IS - 6 N2 - Diastolic heart failure (HF) is also referred to as HF with preserved left ventricular systolic function. The distinction between systolic and diastolic HFs is a pathophysiological one and isolated forms of left ventricular dysfunction are rarely observed. In diastolic HF left ventricular systolic function is normal or only slightly impaired, and the typical manifestations of HF result from increased filling pressure caused by impaired relaxation and compliance of the left ventricle. The predisposing factors for diastolic dysfunction include elderly age, female sex, obesity, coronary artery disease, hypertension and diabetes mellitus. Treatment of diastolic HF is aimed to stop the progression of the disease, relieve its symptoms, eliminate exacerbations and reduce the mortality. The management should include antihypertensive treatment, maintenance of the sinus rhythm, prevention of tachycardia, venous pressure reduction, prevention of myocardial ischemia and prevention of diabetes mellitus. The European Society of Cardiology specifies the type of therapy in diastolic HF based on: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, non-dihydropyridine calcium channel blockers, diuretics. In order to improve the currently poor prognosis in this group of patients the treatment of diastolic HF must be optimised. SN - 1897-5593 UR - https://www.unboundmedicine.com/medline/citation/21154257/Management_of_diastolic_heart_failure_ L2 - http://www.cardiologyjournal.org/en/darmowy_pdf.phtml?id=99&indeks_art=1377 DB - PRIME DP - Unbound Medicine ER -